Peter Schofield Email & Phone Number

Sydney, Nsw, Au

Australia

Pre-launch strategy for rare diseases and management of the Novartis CAR-T therapies portfolio in Australia, working as part of the Novartis Haematology franchise.

Australia

Engaging with Key Opinion Leaders in the field of Haematology, with a focus on Leukaemia, rare diseases, transplant and CAR-T therapies. Ensuring health care professionals have current and deep understanding of therapeutic options. Gathering and communicating actionable medical insights. Delivering high-quality medical activities including medical education events and advisory boards. Experience with pre and post launch products.

Sydney, New South Wales, Australia

Scientific and Medical engagement with KOLs and other HCPs in the haematology therapeutic area. Striving to gain insights on how to achieve the best outcomes for patients treated with CAR-T for lymphoma and leukaemia, and small molecule JAK inhibitors for graft vs host disease. Working strategically in collaboration with two different multifunctional teams with distinct commercial and medical objectives for therapies that are at different stages of the product life cycle.

Sydney, Australia

Postdoctoral and commercial researcher with the Antibody Development Laboratory (ADL) at the Garvan Institute. Conducted successful research into:- The identification of proteins and peptides that play roles or act as markers in various medical conditions.- The creation and validation of monoclonal antibodies as diagnostics and/or therapeutic agents against these targets.- Engineering and optimisation of potential therapeutic antibodies e.g. isotype switching… Show more Postdoctoral and commercial researcher with the Antibody Development Laboratory (ADL) at the Garvan Institute. Conducted successful research into:- The identification of proteins and peptides that play roles or act as markers in various medical conditions.- The creation and validation of monoclonal antibodies as diagnostics and/or therapeutic agents against these targets.- Engineering and optimisation of potential therapeutic antibodies e.g. isotype switching, humanisation, affinity maturation and improvement of biophysical properties.I have over 8 years laboratory experience developing monoclonal antibodies against therapeutic targets and during my PhD against quality-linked breeding markers in commercial wheat varieties. I have also experience in molecular biology, protein chemistry and proteomic analysis. Show less

Darlinghurst, New South Wales, Australia

As a Staff Scientist (PhD, MSc) at the Garvan Institute, I manage a laboratory involved in the discovery and engineering of antibodies with novel characteristics that enhance their potential as therapeutic agents or as medical research tools. Our laboratory is currently providing expertise in the field of antibody and protein engineering in collaborative projects with many other research groups at the Garvan Institute in Sydney, as well as other institutions in Australia and… Show more As a Staff Scientist (PhD, MSc) at the Garvan Institute, I manage a laboratory involved in the discovery and engineering of antibodies with novel characteristics that enhance their potential as therapeutic agents or as medical research tools. Our laboratory is currently providing expertise in the field of antibody and protein engineering in collaborative projects with many other research groups at the Garvan Institute in Sydney, as well as other institutions in Australia and overseas.In addition, I am a technical specialist supervising the Garvan Institute’s Surface Plasmon Resonance (SPR) equipment, which is used to characterise the affinity of interactions between proteins, nucleic acids and other small molecules.I also play an active role in communicating the Garvan Institute’s research activities to non-scientific members of the community on behalf of the Garvan Research Foundation. Show less

Doctor Of Philosophy (Phd), Immunology And Cereal Science

Board-Certified Msl Certificate Of Excellence, 97%